LOS ANGELES (Reuters) - Biogen Idec Inc (BIIB.O: Quote, Profile, Research) and Elan Corp Plc (ELN.I: Quote, Profile, Research) said on Thursday they have notified regulators of two confirmed cases of a potentially deadly brain disease in multiple sclerosis (MS) patients being treated with Tysabri.
